CLX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Clorox Co (CLX) is not a strong buy for a beginner, long-term investor at this time. While the dividend yield is attractive and the company has potential for future growth, the recent financial performance, technical indicators, and lack of positive trading signals suggest that it may be better to wait for clearer signs of recovery before investing.
The technical indicators are bearish. The MACD histogram is negative and contracting, RSI is neutral but leaning towards oversold territory, and moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading near its support level of 103.137, with further downside risk to 100.509. The stock has a 60% chance of declining further in the short term.
may attract value investors.
The company has faced significant challenges, including a 55% stock decline from its peak due to a cyberattack and CRM system issues. Financial performance in Q2 2026 showed declines in revenue (-0.77% YoY), net income (-18.65% YoY), and EPS (-16.77% YoY). Analysts maintain neutral ratings, and there are no significant hedge fund or insider trading trends.
In Q2 2026, Clorox reported revenue of $1.673 billion (-0.77% YoY), net income of $157 million (-18.65% YoY), and EPS of $1.29 (-16.77% YoY). Gross margin dropped to 42.86% (-1.81% YoY). Despite these declines, the company generated $778 million in free cash flow, covering its $602 million dividend costs.
Analysts have raised price targets slightly, but most maintain neutral or hold ratings. The highest price target is $132, and the lowest is $112. Analysts note mixed organic sales trends and challenges in improving margins, but they see potential benefits from the GOJO acquisition in the B2B segment.
